Premium
Effects of Periodontal Therapy on Glycemic Control and Inflammatory Markers
Author(s) -
O'Connell Patricia A.A.,
Taba Mario,
Nomizo Auro,
Foss Freitas Maria C.,
Suaid Flavia A.,
Uyemura Sergio A.,
Trevisan Glauce L.,
Novaes Arthur B.,
Souza Sergio L.S.,
Palioto Daniela B.,
Grisi Marcio F.M.
Publication year - 2008
Publication title -
journal of periodontology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.036
H-Index - 156
eISSN - 1943-3670
pISSN - 0022-3492
DOI - 10.1902/jop.2008.070250
Subject(s) - medicine , glycemic , glycated hemoglobin , periodontitis , gastroenterology , placebo , bleeding on probing , chronic periodontitis , type 2 diabetes , scaling and root planing , diabetes mellitus , insulin , endocrinology , pathology , alternative medicine
Background: Periodontitis, a complication of diabetes mellitus (DM), can induce or perpetuate systemic conditions. This double‐masked, placebo‐controlled study evaluated the effects of periodontal therapy (scaling and root planing [SRP]) on the serum levels of glycated hemoglobin (HbA1c) and on inflammatory biomarkers. Methods: Thirty subjects with type 2 DM and periodontitis were treated with SRP + placebo (SRP; N = 15) or with SRP + doxycycline (SRP+Doxy; N = 15), 100 mg/day, for 14 days. Clinical and laboratory data were recorded at baseline and at 3 months after treatment. Results: After 3 months, the reduction in probing depth was 0.8 mm for the SRP group ( P <0.01) and 1.1 mm for the SRP+Doxy group ( P <0.01) followed by a 0.9% (SRP; P = 0.17) and 1.5% (SRP+Doxy; P <0.01) reduction in HbA1c levels. A significant reduction in interleukin (IL)‐6; interferon‐inducible protein 10; soluble fas ligand; granulocyte colony‐stimulating factor; RANTES; and IL‐12 p70 serum levels were also verified (N = 30). To our knowledge, this is the first report on the effects of periodontal therapy on multiple systemic inflammatory markers in DM. Conclusions: Periodontal therapy may influence the systemic conditions of patients with type 2 DM, but no statistical difference was observed with the adjunctive systemic doxycycline therapy. Moreover, it is possible that the observed improvement in glycemic control and in the reduction of inflammatory markers could also be due to diet, which was not controlled in our study. Therefore, a confirmatory study with a larger sample size and controlled diet is necessary.